Logo image of ORKA

ORUKA THERAPEUTICS INC (ORKA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ORKA - US6876041087 - Common Stock

30.94 USD
-0.5 (-1.59%)
Last: 12/9/2025, 1:38:16 PM
Fundamental Rating

3

ORKA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ORKA as it has an excellent financial health rating, but there are worries on the profitability. ORKA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ORKA has reported negative net income.
ORKA had a negative operating cash flow in the past year.
ORKA had negative earnings in each of the past 5 years.
In the past 5 years ORKA always reported negative operating cash flow.
ORKA Yearly Net Income VS EBIT VS OCF VS FCFORKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -19.96%, ORKA is doing good in the industry, outperforming 76.27% of the companies in the same industry.
ORKA's Return On Equity of -20.88% is amongst the best of the industry. ORKA outperforms 82.86% of its industry peers.
Industry RankSector Rank
ROA -19.96%
ROE -20.88%
ROIC N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ORKA Yearly ROA, ROE, ROICORKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORKA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORKA Yearly Profit, Operating, Gross MarginsORKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

ORKA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ORKA has been increased compared to 5 years ago.
ORKA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORKA Yearly Shares OutstandingORKA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ORKA Yearly Total Debt VS Total AssetsORKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 40.25 indicates that ORKA is not in any danger for bankruptcy at the moment.
ORKA has a Altman-Z score of 40.25. This is amongst the best in the industry. ORKA outperforms 95.86% of its industry peers.
There is no outstanding debt for ORKA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 40.25
ROIC/WACCN/A
WACCN/A
ORKA Yearly LT Debt VS Equity VS FCFORKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 16.94 indicates that ORKA has no problem at all paying its short term obligations.
ORKA's Current ratio of 16.94 is amongst the best of the industry. ORKA outperforms 93.41% of its industry peers.
ORKA has a Quick Ratio of 16.94. This indicates that ORKA is financially healthy and has no problem in meeting its short term obligations.
ORKA has a better Quick ratio (16.94) than 93.41% of its industry peers.
Industry RankSector Rank
Current Ratio 16.94
Quick Ratio 16.94
ORKA Yearly Current Assets VS Current LiabilitesORKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

ORKA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.48%, which is quite impressive.
EPS 1Y (TTM)66.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -2.46% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.29%
EPS Next 2Y11.63%
EPS Next 3Y4.18%
EPS Next 5Y-2.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORKA Yearly Revenue VS EstimatesORKA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 200M 400M 600M 800M 1B
ORKA Yearly EPS VS EstimatesORKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORKA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORKA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORKA Price Earnings VS Forward Price EarningsORKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORKA Per share dataORKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.63%
EPS Next 3Y4.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORKA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORUKA THERAPEUTICS INC

NASDAQ:ORKA (12/9/2025, 1:38:16 PM)

30.94

-0.5 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-04 2026-03-04
Inst Owners92.44%
Inst Owner Change33.62%
Ins Owners2.94%
Ins Owner Change0%
Market Cap1.50B
Revenue(TTM)N/A
Net Income(TTM)-101.63M
Analysts88.89
Price Target47.75 (54.33%)
Short Float %11.48%
Short Ratio11.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.61%
Min EPS beat(2)7.26%
Max EPS beat(2)7.96%
EPS beat(4)4
Avg EPS beat(4)16.82%
Min EPS beat(4)7.26%
Max EPS beat(4)29.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.88%
PT rev (3m)18.53%
EPS NQ rev (1m)-1.89%
EPS NQ rev (3m)-2.4%
EPS NY rev (1m)1.61%
EPS NY rev (3m)-1.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.08
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-2.62
Fwd EYN/A
FCF(TTM)-1.75
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS0
BVpS10.06
TBVpS10.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.96%
ROE -20.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 230.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.94
Quick Ratio 16.94
Altman-Z 40.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)236.67%
Cap/Depr(5y)235.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.33%
EPS Next Y36.29%
EPS Next 2Y11.63%
EPS Next 3Y4.18%
EPS Next 5Y-2.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-90.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-68.31%
EBIT Next 3Y-27.43%
EBIT Next 5YN/A
FCF growth 1Y-1451.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1448.68%
OCF growth 3YN/A
OCF growth 5YN/A

ORUKA THERAPEUTICS INC / ORKA FAQ

What is the fundamental rating for ORKA stock?

ChartMill assigns a fundamental rating of 3 / 10 to ORKA.


What is the valuation status of ORUKA THERAPEUTICS INC (ORKA) stock?

ChartMill assigns a valuation rating of 0 / 10 to ORUKA THERAPEUTICS INC (ORKA). This can be considered as Overvalued.


What is the profitability of ORKA stock?

ORUKA THERAPEUTICS INC (ORKA) has a profitability rating of 1 / 10.


What is the expected EPS growth for ORUKA THERAPEUTICS INC (ORKA) stock?

The Earnings per Share (EPS) of ORUKA THERAPEUTICS INC (ORKA) is expected to grow by 36.29% in the next year.